Macrophage Activation Syndrome (MAS) is a life-threatening hyperinflammatory condition (cytokine storm) occurring as a severe complication of rheumatic diseases such as Still's disease, systemic lupus erythematosus, and Kawasaki disease.
The findings of the international research project METAPHOR have been published in "Arthritis & Rheumatology", evaluating real-world clinical practice and establishing future priorities.
Key Findings and Conclusions
- Treatment Heterogeneity: Management strategies for MAS vary significantly globally depending on physician specialty, regional protocols, and drug availability.
- First-Line Therapy: Glucocorticoids (methylprednisolone) remain the cornerstone of treatment, though early initiation of targeted immunomodulators is recommended to reduce steroid toxicity.
